Granules India Ltd Upgraded to Buy by MarketsMOJO on Strong Technical and Financial Performance

Technical Trends Signal Bullish Momentum

The primary catalyst for the rating upgrade stems from a marked improvement in Granules India’s technical profile. The technical grade shifted from mildly bullish to bullish, supported by a confluence of positive signals across multiple timeframes. On the weekly chart, the Moving Average Convergence Divergence (MACD) indicator remains bullish, corroborated by a bullish MACD on the monthly scale as well. Bollinger Bands also reflect bullish trends on both weekly and monthly charts, indicating sustained upward price momentum.

Daily moving averages are firmly bullish, reinforcing short-term strength. The On-Balance Volume (OBV) indicator, which measures buying and selling pressure, is bullish on both weekly and monthly bases, suggesting accumulation by investors. While the Relative Strength Index (RSI) on the weekly chart shows a bearish signal, the absence of a monthly RSI signal tempers concerns, and the overall technical outlook remains positive. Dow Theory assessments indicate a mildly bullish weekly trend, though the monthly trend remains neutral. Despite mildly bearish readings from the Know Sure Thing (KST) oscillator on weekly and monthly charts, the aggregate technical evidence supports a bullish stance.

Granules India’s current price stands at ₹623.25, close to its 52-week high of ₹636.70, underscoring the stock’s resilience. The stock’s day change was a slight decline of 0.87%, but this minor dip does not detract from the broader positive technical momentum.

Financial Performance Underpins Confidence

Granules India’s financial health has been a key driver behind the upgrade. The company reported its highest-ever quarterly net sales of ₹1,387.94 crores in Q3 FY25-26, reflecting strong demand and operational execution. Operating profit to interest coverage ratio reached an impressive 10.74 times, signalling robust ability to service debt obligations. Cash and cash equivalents surged to ₹619.01 crores in the half-year period, providing ample liquidity and financial flexibility.

Management efficiency remains high, with a return on capital employed (ROCE) of 17.70%, well above industry averages. This metric highlights the company’s effective utilisation of capital to generate profits. The debt to EBITDA ratio is a conservative 0.97 times, indicating low leverage and manageable debt levels. These financial parameters collectively demonstrate a solid foundation for sustainable growth and risk mitigation.

Valuation Remains Attractive Relative to Peers

Granules India’s valuation metrics further justify the upgrade. The company’s ROCE of 14.4% aligns with a fair valuation, supported by an enterprise value to capital employed ratio of 3.2 times. This valuation is at a discount compared to the average historical valuations of its pharmaceutical peers, offering investors an opportunity to buy quality at reasonable prices.

Over the past year, the stock has delivered a total return of 26.72%, significantly outperforming the Sensex’s negative 5.18% return over the same period. The company’s profits have grown by 13.1% year-on-year, resulting in a price-to-earnings-to-growth (PEG) ratio of 2.1, which suggests moderate growth expectations relative to its price. Institutional investors hold a substantial 31.03% stake, reflecting confidence from sophisticated market participants who typically conduct rigorous fundamental analysis.

Quality Metrics and Long-Term Returns

Granules India’s quality scores remain robust, with a MarketsMOJO Mojo Score of 75.0 and a Mojo Grade upgraded to Buy from Hold. The company is classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which has demonstrated consistent outperformance. Over the last three years, the stock has generated a remarkable 119.38% return, vastly exceeding the BSE500 index’s 27.63% gain. Over five and ten years, returns stand at 106.99% and 412.75% respectively, underscoring the company’s long-term growth trajectory.

Despite these positives, investors should be mindful of certain risks. Operating profit growth has averaged a modest 5.92% annually over the past five years, indicating potential challenges in sustaining high growth rates. This slower profit expansion could temper expectations for future earnings acceleration.

Comparative Returns Highlight Market Outperformance

Granules India’s stock performance relative to the Sensex further validates the upgrade. In the last week, the stock returned 5.49% compared to the Sensex’s decline of 1.27%. Over one month, the stock gained 7.15% while the Sensex fell 9.48%. Year-to-date returns stand at 4.13% for Granules India versus a negative 13.66% for the Sensex. This consistent outperformance extends to longer horizons, with the stock delivering 26.72% over one year against the Sensex’s -5.18%, and an impressive 412.75% over ten years compared to the Sensex’s 190.41%.

Such sustained relative strength highlights the company’s resilience and ability to generate shareholder value even in challenging market environments.

Conclusion: A Balanced Upgrade Reflecting Strengths and Risks

The upgrade of Granules India Ltd from Hold to Buy is well supported by a comprehensive improvement across technical indicators, financial performance, valuation attractiveness, and quality metrics. The company’s strong quarterly results, high management efficiency, and solid liquidity position underpin confidence in its near-term prospects. Technical trends have turned decisively bullish, signalling positive momentum for the stock price.

While the company’s operating profit growth rate over the past five years suggests some caution regarding long-term expansion, the overall outlook remains favourable. Institutional backing and consistent outperformance relative to benchmarks further enhance the investment case.

Investors seeking exposure to the Pharmaceuticals & Biotechnology sector may find Granules India an appealing candidate for portfolio inclusion, given its blend of quality, value, and technical strength.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today